

CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, November 24, 2020

In accordance with article 227 of the recast Spanish Securities Market Act (*texto refundido de la Ley del Mercado de Valores*), approved by Royal Legislative Decree 4/2015, of 23 October, and related provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

The Company reports that its subsidiary Genomica, S.A.U. (“GENOMICA”), the molecular diagnostic company belonging to Group Pharma Mar, is making its new PCR test, *qCOVID-19 Respiratory COMBO* available to hospitals and diagnostic laboratories for the differential detection of SARS-CoV-2, A and B Influenza strains and respiratory syncytial virus (RSV). This innovation, which has obtained a CE marking, has been carried out by GENOMICA’s R&D team in Madrid.

The new *qCOVID-19 Respiratory COMBO* test has now successfully completed trials carried out with nasopharyngeal samples from patients with additional/other respiratory infections at the ‘Hospital Universitario La Paz’, the ‘Hospital Clínico Universitario de Valencia’ and the ‘Hospital Universitario y Politécnico La Fe’, in Valencia.

GENOMICA’s test obtained sensitivities of over 95% and specificities of over 99.7%. The Company's diagnostic PCR kit has therefore proven to be highly sensitive and specific in differentiating and detecting respiratory viruses, including SARS-CoV-2, even allowing for the detection of asymptomatic cases.

This new test, is PCR based, a reference method for virus detection that makes it possible to differentiate SARS-CoV-2 virus, which is the cause of the current COVID-19 pandemic, from other viruses. This is clinically important, due to the similarity of the symptoms caused by these common respiratory diseases: Influenza A and B, as well as infections caused by RSV. A rapid and accurate diagnosis can be done within hours, which ultimately allows doctors to classify patients and determine the most appropriate treatment and isolation measures for each case.

The product is now commercially available and is compatible with Real Time PCR or qPCR technology, a widely used technology for diagnosis in hospitals, health centers or diagnostics laboratories.

Please find attached press release that will be distributed to the media today.

GENOMICA, PharmaMar Group, launches a new PCR test that can detect and differentiate SARS-CoV-2, Influenza A and B and Respiratory Syncytial Virus (RSV)

- **GENOMICA has received a CE marking for its new qCOVID-19 Respiratory Combo, a new multi-viral PCR test for COVID-19, A and B 'flu and RSV diagnostics.**
- **The Company has successfully completed the validation carried out in collaboration with three Spanish hospitals.**
- **The new GENOMICA test has obtained a sensitivity and specificity of approximately 100%.**

Madrid, November 24th, 2020- GENOMICA, the molecular diagnostics Company belonging to the PharmaMar Group (MSE:PHM), is making its new PCR test, **qCOVID-19 Respiratory COMBO** available to hospitals and diagnostic laboratories for the differential detection of SARS-CoV-2, A and B Influenza strains and respiratory syncytial virus (RSV). This innovation, which has obtained a CE marking, has been carried out by GENOMICA's R&D team in Madrid.

The new **qCOVID-19 Respiratory COMBO** test has now successfully completed trials carried out with nasopharyngeal samples from patients with additional/other respiratory infections at the 'Hospital Universitario La Paz', the 'Hospital Clínico Universitario de Valencia' and the 'Hospital Universitario y Politécnico La Fe', in Valencia.

GENOMICA's test obtained sensitivities of over 95% and specificities of over 99.7%. The Company's diagnostic PCR kit has therefore proven to be highly sensitive and specific in differentiating and detecting respiratory viruses, including SARS-CoV-2, even allowing for the detection of asymptomatic cases.

This new test, is PCR based, a reference method for virus detection that makes it possible to differentiate SARS-CoV-2 virus, which is the cause of the current COVID-19 pandemic, from other viruses. This is clinically important, due to the similarity of the symptoms caused by these common respiratory diseases: Influenza A and B, as well as



infections caused by RSV. A rapid and accurate diagnosis can be done within hours, which ultimately allows doctors to classify patients and determine the most appropriate treatment and isolation measures for each case.

The product is now commercially available and is compatible with Real Time PCR or qPCR technology, a widely used technology for diagnosis in hospitals, health centers or diagnostics laboratories.

GENOMICA has commercial agreements in over 20 countries around the world.

The Company remains committed to supplying Spanish institutions. Since the launch of the first COVID-19 PCR kit with the CE marking up to today, thousands of patients have been tested for SARS-CoV-2 with GENOMICA's kits, which are manufactured at its facilities located in Madrid. Now, this new kit will provide both Spanish and international hospitals with a new tool in the fight against COVID-19, seasonal 'flu and other viruses that have very similar initial symptoms, helping in a rapid and accurate diagnosis.

Coronaviruses are an extended family of viruses that can cause the common cold, other more serious diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).

INGESA Framework Agreement

GENOMICA is one of the awarded companies in the Ministry of Health Framework Agreement that the National Institute of Health Management (INGESA) has put out to tender, for the supply of up to 7.5 million COVID-19 molecular diagnostics tests, and will be supplied on demand from the participating hospitals and/or diagnostic laboratories.

The Company makes its **qCOVID-19 Respiratory COMBO** test available for sale exclusively to hospitals and professional molecular biology laboratories and requires instrumentation and qualified personnel. For more information on **qCOVID-19 Respiratory COMBO**, please contact the GENOMICA team at covid-19@genomica.com. More information at genomica.com

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.



About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About GENOMICA

GENOMICA is highly experienced in the analysis of genetic identification. Founded in 1990, with facilities in Madrid, GENOMICA is 100% owned by PharmaMar. It is our mission to improve the present molecular diagnostics tools and the human identification methods through reliability and automation.

Our main objective is to maintain leadership in genomics applications within the Spanish market, and to internationally extend our activities in the area of Molecular Diagnostics by means of the design, development, automation, and commercialization of new diagnostic applications of our innovative technological platform, Clinical Arrays Technology, CLART®.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Móvil : + 34609493127

Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Móvil: +34 606597464

Álvaro Mateo - Communication Manager amateo@pharmamar.com Móvil: +34 650726009

Teléfono: +34 918466000



Investor Relations:

Phone: +34 914444500

Or please visit our website at www.pharmamar.com